Endometrial Cancer clinical trials in New Hampshire

1 actively recruiting endometrial cancer trials at 1 site across New Hampshire.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Eli Lilly and Company funds and runs this clinical trial (NCT04956640). In 2024, Eli Lilly and Company reported paying the doctors leading the trial a total of $5,294,078 for research work on this study.

Who paid

Eli Lilly and Company $5,294,078

Paid for research work on this trial

YONINA MURCIANO-GOROFF $587,219
NATRAJ AMMAKKANAVAR(oncologist on CancerDrs) $580,287
SO YEON KIM(oncologist on CancerDrs) $464,502
TIMOTHY BURNS(oncologist on CancerDrs) $418,889
JOSEPH BODOR(oncologist on CancerDrs) $374,463

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Research payments are not, by themselves, a conflict — paying for legitimate trial work is how drug development gets funded. The purpose of Sunshine Act disclosure is to give patients the context, not to make the decision for them.

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Phase 1, Phase 2 Recruiting Industry

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the sta…

Sponsor: Eli Lilly and Company

NCT ID: NCT04956640

Sites in New Hampshire:

Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20